E. Coli Patogenik

01Pathophysiology

Pathogenic E. coli strains are distinguished from commensal E. coli by the acquisition of virulence factors, typically through plasmids, pathogenicity islands, or bacteriophage-mediated gene transfer. Each pathotype uses a different strategy to cause disease, and understanding these mechanisms is the key to predicting the clinical picture in a vignette.

Enterotoxigenic E. coli (ETEC) is the leading bacterial cause of traveler's diarrhea. It colonizes the small intestinal mucosa using colonization factor antigens (CFAs) and produces two enterotoxins. The heat-labile toxin (LT) activates adenylate cyclase via a mechanism identical to cholera toxin, increasing intracellular cyclic AMP (cAMP), which drives chloride secretion and inhibits sodium absorption. The heat-stable toxin (ST) activates guanylate cyclase, raising cyclic GMP (cGMP) with the same net secretory effect. The result is a watery, non-bloody diarrhea with no mucosal destruction and no fecal leukocytes, because the toxins act on intact enterocytes without invasion.

Enteropathogenic E. coli (EPEC) primarily affects infants and young children in developing countries. EPEC uses a type III secretion system encoded by the locus of enterocyte effacement (LEE) pathogenicity island. The bacterium attaches intimately to enterocytes and injects effector proteins that destroy the brush border microvilli, producing the hallmark attaching and effacing (A/E) lesion. The destruction of microvilli leads to malabsorption and osmotic-secretory diarrhea. Because there is no tissue invasion, stool is watery and non-bloody, and fecal leukocytes are absent.

Enterohemorrhagic E. coli (EHEC), also called Shiga toxin-producing E. coli (STEC), is the most heavily tested pathotype. The prototype serotype is O157:H7. EHEC colonizes the large intestine and produces Shiga-like toxins (Stx1 and Stx2) encoded by lysogenic bacteriophages. These toxins bind to the globotriaosylceramide (Gb3) receptor on endothelial cells, inhibit the 60S ribosomal subunit, and halt protein synthesis, leading to endothelial cell death. In the colon, this causes hemorrhagic colitis with bloody diarrhea that is characteristically afebrile (or only low-grade fever). Systemically, Shiga toxin damages the renal glomerular endothelium, triggering a thrombotic microangiopathy known as hemolytic uremic syndrome (HUS), defined by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. HUS occurs in approximately 5 to 15 percent of EHEC infections in children and is the most common cause of acute renal failure in pediatric patients.

Enteroinvasive E. coli (EIEC) behaves clinically like Shigella. It invades and destroys the colonic epithelium using a plasmid-encoded type III secretion system. The organism penetrates the mucosal cells, multiplies intracellularly, and spreads laterally to adjacent cells, causing ulceration and inflammation. This produces a dysentery syndrome with fever, abdominal cramps, and mucoid bloody stools with abundant fecal leukocytes, mirroring Shigella infection.

Enteroaggregative E. coli (EAEC) adheres to the intestinal mucosa in a characteristic "stacked brick" pattern and produces a biofilm on the mucosal surface. It elaborates enterotoxins and cytotoxins that cause low-grade mucosal inflammation and secretory diarrhea. EAEC is a recognized cause of persistent diarrhea (lasting more than 14 days) in children in developing countries and in immunocompromised patients, including those with HIV.

02Classification and Clinical Manifestation

A useful simplification for exam recall:

03Diagnostic Workup

The best initial test when EHEC is suspected (bloody diarrhea, particularly in a child after consuming undercooked beef) is simultaneous stool culture on sorbitol-MacConkey agar and Shiga toxin assay. Current guidelines recommend ordering both together because sorbitol-MacConkey agar only identifies serotype O157:H7, while the toxin assay captures all STEC serotypes including non-O157 strains (such as O104:H4 and O26), which account for a growing proportion of cases.

For non-EHEC pathotypes (ETEC, EPEC, EIEC, EAEC), standard stool culture will grow E. coli but cannot distinguish pathogenic from commensal strains by colony morphology alone. Definitive identification requires molecular methods such as multiplex PCR panels that detect pathotype-defining virulence genes (e.g., elt/est for ETEC, eae for EPEC, ipaH for EIEC, aatA/aggR for EAEC). In clinical practice, many hospital laboratories now use syndromic gastrointestinal PCR panels that can identify these targets directly from stool.

When EHEC infection is confirmed or strongly suspected, the critical next step is serial monitoring for HUS with daily CBC, peripheral smear, reticulocyte count, BMP, LDH, and urinalysis for at least 7 to 10 days after symptom onset. HUS typically develops 5 to 10 days after the onset of diarrhea, often as the diarrhea itself is improving, which is a classic exam scenario.

The fecal leukocyte test or stool lactoferrin serves as a rapid triage tool. Positive results point toward invasive organisms (EIEC, Shigella, Salmonella, Campylobacter) and away from toxin-mediated or adherence-based pathogens (ETEC, EPEC, EHEC).

04Management and Treatment

Acute Stabilization (All Pathotypes)
The cornerstone of treatment for all diarrheal illnesses caused by pathogenic E. coli is fluid and electrolyte replacement. For mild to moderate dehydration, oral rehydration solution (ORS) is the standard of care, particularly in pediatric patients and in resource-limited settings. For severe dehydration (altered mental status, inability to drink, hemodynamic instability), intravenous isotonic crystalloid (normal saline or lactated Ringer's) should be initiated immediately. Volume status, urine output, and electrolytes should be monitored closely.

ETEC (Traveler's Diarrhea)
Most ETEC infections are self-limited, resolving within 3 to 5 days. Antibiotic therapy shortens symptom duration and is recommended for moderate to severe cases. Azithromycin (1000 mg as a single dose or 500 mg once daily for 3 days) is the preferred first-line agent, particularly in Southeast Asia and South Asia where fluoroquinolone resistance is common. Ciprofloxacin (500 mg twice daily for 1 to 3 days) remains effective in regions with low resistance. Rifaximin (200 mg three times daily for 3 days) is an option for non-dysenteric traveler's diarrhea only; it should not be used if there is bloody stool or fever, as it does not achieve systemic levels. Loperamide may be used as adjunctive therapy in adults with non-dysenteric disease but should be avoided in children under 2 years.

EHEC and HUS Prevention
This is the most tested management principle. When a vignette describes a child with bloody diarrhea after eating undercooked meat, the correct answer is supportive care with IV fluids and close monitoring. Antibiotics are contraindicated because they cause bacterial lysis, releasing large quantities of preformed Shiga toxin and significantly increasing the risk of HUS. Antimotility agents (loperamide) are also contraindicated because they slow toxin clearance from the gut. If HUS develops, management is supportive: dialysis for renal failure and severe electrolyte abnormalities, packed red blood cell transfusions for severe anemia (maintain hemoglobin above 6 to 7 g/dL), and cautious platelet transfusion only for active bleeding or before invasive procedures (routine platelet transfusion may worsen thrombotic microangiopathy). Eculizumab, a complement inhibitor (anti-C5 monoclonal antibody), has been used in severe or atypical HUS cases, though evidence in typical STEC-HUS remains limited.

EIEC
Management mirrors that of shigellosis. Empiric antibiotic therapy with azithromycin or a fluoroquinolone is appropriate, along with aggressive rehydration.

Contraindications and Cautions
Fluoroquinolones (ciprofloxacin, levofloxacin) should be avoided in pregnant women and children under 18 due to the risk of cartilage toxicity (though the absolute risk is debated, exam questions test the classic teaching). TMP-SMX is avoided in late pregnancy (risk of kernicterus) and in patients with sulfa allergy. Metronidazole has no role in E. coli diarrhea and should not be selected.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most tested concept in pathogenic E. coli questions is the contraindication of antibiotics in EHEC infection. The classic trap presents a child with bloody diarrhea, a positive stool culture for E. coli O157:H7, and asks for the next best step. Students who select an antibiotic (even a correct one for other diarrheal pathogens) will get this wrong. The answer is always supportive care with IV hydration and monitoring for HUS. This tests whether you understand that antibiotic-induced bacterial lysis amplifies Shiga toxin release.

A second common trap involves the absence of fever and fecal leukocytes in EHEC. Students see bloody diarrhea and reflexively associate it with invasive disease (Shigella, EIEC, Salmonella), all of which produce fever and fecal leukocytes. EHEC is the exception: it causes bloody diarrhea through toxin-mediated vascular endothelial damage, not mucosal invasion, so the patient is afebrile and fecal leukocytes are absent. A vignette describing "bloody diarrhea without fever" in a child who recently ate a hamburger is essentially giving you the diagnosis.

A third pearl involves the timing of HUS. Exam vignettes may present a child who had diarrhea that is now improving, but new lab findings show anemia, thrombocytopenia, and rising creatinine. Students may be confused because the gastrointestinal symptoms are resolving. HUS characteristically develops 5 to 10 days after diarrhea onset, often during the recovery phase, and this temporal pattern is a favorite testing point.

For ETEC, the core competency tested is recognizing the classic traveler's diarrhea scenario: a person who recently returned from a developing country with acute watery (not bloody) diarrhea. The distractor is usually cholera, but cholera causes far more severe "rice-water" diarrhea with rapid hemodynamic collapse.

Finally, remember that sorbitol-MacConkey agar only identifies O157:H7 by its failure to ferment sorbitol. Non-O157 STEC strains (which are increasingly recognized as causes of HUS) will ferment sorbitol and appear as normal colonies, making them invisible on this medium. That is why current guidelines recommend pairing the culture with a Shiga toxin immunoassay or PCR. A question may describe a child with classic EHEC presentation but a "negative" sorbitol-MacConkey culture, testing whether you know to order the toxin assay to catch non-O157 serotypes.